Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Declan Doogan, Insider at Biohaven Pharma Hldgs (NYSE:BHVN), made a large buy and sell of company shares on November 16, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Declan Doogan exercised options to purchase 559,000 Biohaven Pharma Hldgs shares at prices ranging from $0.61 to $61.76 per share for a total of $4,398,760 on November 16. They then sold their shares on the same day in the open market. They sold at prices
Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development programNEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd. (“Biohaven”, parent company NYSE:BHVN), a commercial-stage Neuroinnovation company, today announced the companies are initiating a therapeutic discovery and dev
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that NURTEC® ODT (rimegepant) was approved by the Kuwait Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that enrollment is now complete in the verdiperstat arm of the HEALEY ALS Platform Trial. This first-ever platform trial in ALS, sponsored by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), is designed to evaluate the safety and efficacy of multiple drug candidates in people with Amyotrophic Lateral Sclerosis ("ALS"). Verdiperstat was selected as one of the inaugural investigat
John Childs, Insider at Biohaven Pharma Hldgs (NYSE:BHVN), made a large insider buy on November 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Childs purchased 5,000 shares of Biohaven Pharma Hldgs at at prices ranging from $122.75 to $123.30. The total transaction amounted to $614,342. Childs now owns a total of 2,560,801 of Biohaven Pharma Hldgs worth, 314,184,674. Biohaven Pharma Hldgs shares are trad
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
In his first "Executive Decision" segment of Wednesday's Mad Money program, Jim Cramer spoke with Vlad Coric, CEO of Biohaven Pharmaceutical , the biotech. Biohaven just announced a global partnership with Pfizer to bring its migraine treatment, Nurtec ODT, to patients outside the U.S. Coric said in the deal, Biohaven retains the U.S. rights to Nurtec, but leverages Pfizer's global presence to commercialize the drug around the globe.
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.